Hims & Hers Health, Inc. HIMS is fundamentally built around expanding access to healthcare by shifting traditionally fragmented, in-person experiences into a more seamless digital model. Its platform connects consumers to licensed providers, enabling telehealth consultations, digital prescriptions and online fulfillment, all designed to make care faster, and more convenient and affordable. By integrating these capabilities, HIMS aims to reduce longstanding barriers such as stigma, cost and limited provider availability, while delivering personalized care across a wide range of conditions.
Recent developments reinforce this access-driven strategy. Hims & Hers has continued to broaden the availability of treatments by partnering with Novo Nordisk to offer FDA-approved GLP-1 medications at more affordable prices and through multiple delivery formats, simplifying access for eligible patients. At the same time, it has expanded proactive care through new offerings such as multi-cancer early detection testing and its Labs platform, both of which are designed to make advanced diagnostics more accessible and actionable for everyday consumers.
Geographic expansion has further extended this mission. Through acquisitions and market entries, Hims & Hers is scaling its digital-first model globally, including in Canada and Europe, with a focus on bringing affordable, personalized care to populations where access has historically been limited. Together, these initiatives reflect a consistent effort to democratize healthcare — making high-quality, personalized care more accessible across conditions, formats and geographies.
Hims & Hers is scheduled to report first-quarter 2026 results on May 11, after the closing bell.
GDRX and TDOC Expanding Digital Healthcare Access
GoodRx Holdings, Inc. GDRX is advancing digital-first healthcare access by simplifying how consumers find, afford and receive treatments. GDRX has expanded condition-specific subscriptions, including services for hair loss and erectile dysfunction that combine virtual consultations, prescriptions and home delivery into a single streamlined experience, reducing barriers such as cost and inconvenience. At the same time, GoodRx continues to scale affordability through partnerships and pricing innovations. GoodRx enables access to high-cost therapies like GLP-1 treatments with transparent self-pay pricing, while also integrating savings directly at the pharmacy counter through programs like RxSmartSaver.
Teladoc Health, Inc. TDOC is advancing digital-first healthcare access by delivering comprehensive virtual care across physical and mental health needs through its Integrated Care and BetterHelp platforms. Teladoc Health connects patients, providers and systems to enable 24/7 access to services spanning preventive, primary, chronic and mental healthcare, improving outcomes while lowering costs. Teladoc Health recently enhanced its 24/7 Care service to treat a broader range of conditions, integrate specialist input and streamline referrals, further expanding access and care continuity through its technology-driven ecosystem.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 14.1% year to date compared with the industry’s decline of 21.8%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.1X is lower than the industry’s average of 3.4X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 5.7% improvement compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teladoc Health, Inc. (TDOC): Free Stock Analysis Report
GoodRx Holdings, Inc. (GDRX): Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).